The company made the announcement today at the 2016 Molecular Medicine Tri-Conference (Tri-Con) in San Francisco. This marks the official launch of its U.S. custom services and innovation division to better serve its customers and partnerships for molecular diagnostic development, clinical and translational research, and other life science and agricultural applications. With company headquarters in Seoul, South Korea, this new division will serve as the technology innovation arm of the parent corporation. The U.S. offices are located in Concord, California.
In addition, Seegene plans future submissions to the U.S. Food & Drug Administration (FDA) of multiplex tests in the areas of infectious disease, such as respiratory disease, gastrointestinal infections and women’s health. In February 2015, Seegene obtained its first 510(k) market clearance for its TOCE™-based herpes simplex virus (HSV) types 1 and 2 assay. Seegene has announced other strategic partnerships with global diagnostic companies and will continue to seek and support global diagnostic partnerships for molecular and companion diagnostic development.
According to Dr. Jong-Yoon Chun, CEO and Founder of Seegene, “Our success at providing complex, yet cost-effective, multiplex PCR molecular diagnostic assays throughout Europe, Asia, Canada, Middle East and Latin America provides us with a solid foundation from which to build on to serve the U.S. market as well.”
Seegene’s technology and clinical utility will be demonstrated during two speaker presentations during Tri-Con, both of which are open to the press:
· “‘Fit-for-Workflow’ considerations for designing multiplex PCR assays for SNP detection and target enrichment,” led by Young Kim, Ph.D., Lead Application Scientist, Seegene is scheduled on Tuesday, March 8 at 3:40 p.m. PST. Conventional approaches to assay development using PCR are generally limited to very few targets, which is not an ideal companion to NGS. Using examples from BCR-ABL, thrombosis, HPV genotyping, and others, we will discuss novel approaches to develop high-multiplex RT-PCR and qPCR assays that achieve high-throughput, target complexity, specificity and sensitivity.
· “Molecular Diagnostics for Infectious Disease - Advancing Microbial Diagnostics to Improve Detection and Patient Outcome,” led by Diane Hirigoyen, M.S., Lead Molecular Specialist, University of Minnesota, Hennepin County Medical Center (HCMC), will be a lunch symposium beginning at 12:40 p.m. PST on Wednesday, March 9, 2016. The session will include a discussion about the increase in the incidence of active TB among certain U.S. populations, resulting in increased detection of multi-drug resistant (MDR) and extreme resistant (XDR) strains of TB as a result. The session will share the experience of The Mycobacteriology Laboratory at HCMC and results on the emergence of TB and TB-like diseases in an inner city and active immigrant community.
Seegene will exhibit in Booth 223 at Tri-Con in San Francisco from March 7-9, 2016. For more information, visit http://www.seegene.com/neo/en/news/seegene/list.php
Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies DPO™, TOCE™, and MuDT™, are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160307005301/en/
- Media Contact
- Chempetitive Group for Seegene